NCT06821503 2026-03-10
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT05576480 2025-08-28
SPARC
Ruijin Hospital
Phase 2 Recruiting
NCT07075419 2025-07-20
JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure
West China Hospital
Phase 1/2 Not yet recruiting
NCT06853769 2025-03-03
LARC-nCR01
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1 Active not recruiting
NCT05229003 2024-07-03
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Fudan University
Phase 2 Recruiting
NCT05493995 2024-05-09
PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Completed
NCT06010901 2024-01-23
A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Unknown
NCT05494060 2023-11-07
EXPLORING
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06051851 2023-09-25
RCT-PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting
NCT05862337 2023-05-17
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT05519202 2022-08-29
Exploratory Clinical Study of Penpulimab Combined With SOX in the Perioperative Treatment of Gastric Cancer
The Central Hospital of Lishui City
Phase 2 Unknown
NCT04970914 2022-03-08
ALTER-C003
Peking Union Medical College Hospital
Phase 2 Unknown
NCT05265962 2022-03-04
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown